Category: Partners

GoodData recognized by Gartner® for ability to execute and completeness of vision.

SAN FRANCISCO, CA / ACCESS Newswire / June 18, 2025 / GoodData, the AI-native analytics platform, today announced its inclusion in the 2025 Gartner® Magic Quadrant™ for Analytics and Business Intelligence Platforms. Recognized as a Niche Player, GoodData was acknowledged for its ability to execute and completeness of vision.

At the core of GoodData’s platform is its composability strategy, powered by open source technology, multi-tenancy framework, and an open semantic layer, giving data teams the ability to define metrics once and reuse them across every dashboard, application, or tool in the enterprise. This ensures consistent, governed insights at scale while aligning analytics with business logic and objectives.

“GoodData was built for a world where analytics isn’t a nice-to-have. It is a critical part of the enterprise data landscape, and we believe that our inclusion in the Gartner Magic Quadrant is a testament to the demand for interoperable analytics platforms that treat analytics as code and fit seamlessly into the modern DevOps and product development lifecycle.”

Roman Stanek, CEO and Founder of GoodData.

With its analytics-as-code approach, GoodData enables development teams to build and extend data experiences like any other software component. This empowers teams to automate development with CI/CD pipelines, fully customize the user experience through APIs and embedded components, and ensure trust in the data through automated testing and version control.

Additionally, GoodData’s commitment to interoperability sets it apart. Native features like FlexConnect and metadata ingestion from third-party BI tools allow teams to unify data across silos and ecosystems without duplicating or moving data. The platform’s zero-copy architecture enhances performance while maintaining data integrity and governance.

“GoodData’s flexibility to integrate into any backend setup has proven to provide maximum flexibility for our engineering needs.”

VP, Product in the Banking sector; from Gartner® Peer Insights™ review

“The future of BI is not in monolithic dashboards – it’s in flexible, embedded, and governed insights that live where decisions are made. By focusing on analytics-as-code and end-to-end composability, we’re equipping data and product teams with the tools they need to innovate faster and smarter.”

Ryan Dolley, VP of Product Strategy at GoodData

In our opinion, GoodData’s position in the Magic Quadrant underscores a market shift toward developer-centric analytics platforms that seamlessly integrate into today’s complex data stacks and product environments. Read the full Gartner® Magic Quadrant™ report to see a complete analysis of GoodData’s strengths and cautions.

---

GARTNER is a registered trademark and service mark of Gartner and Magic Quadrant and Peer Insights are a registered trademark, of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.

Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences with the vendors listed on the platform, should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.

Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

---

About GoodData

GoodData is the AI-native analytics platform built for speed, scale, and trust, helping companies deliver real-time insights – embedded, branded, and everywhere your users need them.

Founded in 2007, and with offices in both the U.S. and Europe, GoodData serves over 140,000 of the world’s top companies and 3.2 million users, helping them drive meaningful change and maximize the value of their data.

For more information, visit GoodData’s website and follow GoodData on LinkedIn, YouTube, and Medium.

GoodData Contact
press@gooddata.com

©2025, GoodData Corporation. All rights reserved. GoodData and the GoodData logo are registered trademarks of GoodData Corporation in the United States and other jurisdictions. Other names used herein may be trademarks of their respective owners.

SOURCE: GoodData

View the original press release on ACCESS Newswire

Study used cell lines obtained from the Progeria Research Foundation to evaluate Telomir-1’s effects on key drivers of accelerated aging

MIAMI, FLORIDA / ACCESS Newswire / June 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a preclinical-stage biotechnology company focused on reversing biological aging and age-related diseases, today announced compelling new preclinical data showing that its lead candidate, Telomir-1, prevented cellular aging in human progeria cell lines obtained from the Progeria Research Foundation. Progeria, or Hutchinson-Gilford Progeria Syndrome (HGPS), is an ultra-rare pediatric disorder caused by a mutation in the LMNA gene. This mutation results in the production of an abnormal protein called progerin, which drives rapid biological aging in children.

There are an estimated 400-500 known cases worldwide, including fewer than 30 children currently living with the disease in the United States. Symptoms typically begin within the first two years of life and include growth failure, joint stiffness, loss of body fat and hair, and severe cardiovascular disease. Children with progeria have an average life expectancy of just 13 to 15 years, with most dying from heart attacks or strokes at a young age.

The only FDA-approved therapy for progeria, Zokinvy® (lonafarnib), is a farnesyltransferase inhibitor that has been shown to extend lifespan by an average of 4.3 years. However, Zokinvy does not reverse the underlying disease pathology or halt cardiovascular deterioration, which remains the leading cause of death. No approved therapy restores normal cell function or reverses the biological hallmarks of accelerated aging in progeria, highlighting a significant and urgent unmet medical need.

Telomir-1 is designed to regulate intracellular metal ions, reduce oxidative stress, restore mitochondrial function, extend telomere length, reverse muscle loss, and reset age-associated DNA methylation patterns – all of which are critical biological pathways implicated in progeria and broader age-related diseases.

In this study, conducted by Smart Assays, Telomir-1 was tested in cells taken directly from a child with HGPS. These cells were obtained from The Progeria Research Foundation (www.progeriaresearch.org). The study evaluated cell viability, reactive oxygen species (ROS), and intracellular calcium signaling – a marker of mitochondrial dysfunction – under both normal and stress-induced conditions.

Key findings include:

• Improved cell viability: Telomir-1 increased survival in a dose-dependent manner, both under basal conditions and even under stress conditions induced by copper and iron-two metal ions known to accelerate aging by generating oxidative damage and destabilizing DNA and telomeres.

• Reduction of oxidative stress: Progeria cells exhibited abnormally high levels of reactive oxygen species (ROS), a hallmark of cellular aging. Telomir-1 normalized these levels, both under basal conditions and even when ROS was further elevated by toxic metal exposure.

• Restoration of mitochondrial function: Iron-induced calcium overload – a signal of mitochondrial damage and a known feature of HGPS – was significantly reduced with Telomir-1, indicating restored mitochondrial regulation and improved cellular energy balance.

These results demonstrate that Telomir-1 directly addresses the core cellular dysfunctions driving disease features in progeria – not only protecting cells from damage but restoring critical biological functions. The fact that these results were observed in actual patient-derived human cells offers strong early validation of Telomir-1’s therapeutic potential.

“These results provide the strongest evidence to date that Telomir-1 is not only protective but also restorative at the molecular and cellular level,” said Dr. Angel, Chief Scientific Advisor of Telomir. “What’s especially promising is that the improvements we observed directly target the mechanisms known to drive disease progression in progeria – oxidative stress, metal toxicity, and mitochondrial instability. This level of functional rescue in actual patient-derived cells is highly encouraging as we move toward clinical translation. These studies come as further validation of the very promising results obtained previously in both nematode and zebrafish models of adult progeria.”

“These findings deepen our conviction that Telomir-1 can be a first-in-class therapeutic platform for rare aging syndromes and broader age-related diseases,” said Erez Aminov, CEO of Telomir. “By demonstrating the ability to reverse cellular damage in human progeria cells, Telomir-1 represents a potential breakthrough for children who currently have no real options beyond modestly delaying the inevitable. This work also lays the foundation for broader applications in neurodegeneration, metabolic dysfunction, and systemic aging.

The new data also build on previously reported studies in zebrafish and C. elegans nematodes harboring the wrn gene mutation (a model of adult progeria, or Werner syndrome), where Telomir-1 significantly extended lifespan, restored telomere length, reversed muscle degeneration, and normalized molecular age markers.

Telomir is currently finalizing IND-enabling studies for Telomir-1 and plans to engage with the U.S. Food and Drug Administration (FDA) to explore regulatory pathways, including the potential for orphan drug designation. The company is evaluating multiple rare disease indications for initial clinical development.

Cautionary Note Regarding Forward-Looking Statements

This press release, statements of Telomir’s management or advisors related thereto, and the statements contained in the news story linked in this release contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.

Any forward-looking statements in this press release are based on Telomir’s current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir’s programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which are on file with the SEC and available at www.sec.gov. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Helga Moya
info@telomirpharma.com
(786) 396-6723

SOURCE: Telomir Pharmaceuticals, Inc

View the original press release on ACCESS Newswire

SIOUX FALLS, SD / ACCESS Newswire / June 18, 2025 / Avel eCare, a leading provider of telemedicine services, today announced a strategic partnership with Alliant Purchasing, one of the nation’s largest independent Group Purchasing Organizations (GPOs), to bring innovative virtual care solutions to more than 35,000 healthcare provider organizations across the U.S.

Through this partnership, Alliant Purchasing members, including rural and urban hospitals, clinics, and long-term care facilities, will gain preferred pricing and streamlined access to Avel eCare’s full suite of 10 virtual service lines. The services are designed to help address critical healthcare challenges, including clinical staffing shortages, the need to keep care local, and the ongoing demand for high-quality, affordable care across the healthcare continuum.

“We are excited to bring Avel’s expertise and services to our members,” said Kary LeBlanc, COO of Alliant Purchasing. “Avel’s telemedicine solutions offer an important opportunity for our members, particularly those in rural communities, to expand access to care while improving outcomes and addressing staffing challenges. By integrating Avel into our vendor options, Alliant members now have a seamless and cost-effective path to virtual care implementation.”

Under the partnership, Alliant Purchasing members will have preferred access and pricing on Avel’s extensive telemedicine service portfolio:

• Emergency

• Hospitalist

• Pharmacy

• Behavioral Health

• ICU (Critical Care)

• Virtual Nursing

• School Health

• EMS Support

• Senior Care

“This partnership directly supports Avel’s mission of helping healthcare providers-large and small-thrive in today’s challenging environment,” said Doug Duskin, CEO of Avel eCare. “Together, we are empowering providers to meet growing patient needs, improve care quality, and ease the burden on overstretched clinical teams. This is especially vital for rural hospitals, where staffing shortages often threaten the ability to keep care local.”

Avel’s services are backed by more than 30 years of clinical and telemedicine innovation, providing 24/7 access to board-certified specialists and delivering proven results.

About Alliant Purchasing
For more than 30 years, Alliant Purchasing has served a diverse group of healthcare providers nationwide. Originally conceived by a large urban healthcare system to assist small rural hospital partners, Alliant continues its tradition of combining divergent interests to create collective value. Today, Alliant serves more than 230 hospital members and over 35,000 members and leverages more than $84 billion in buying power to simplify the healthcare supply chain and provide transformational value. For more information, visit https://www.alliantpurchasing.com

About Avel eCare
Avel eCare is a national leader in technology enabled clinical services delivered through telemedicine, delivering provider-to-provider virtual care solutions that expand clinical capacity and improve outcomes across the healthcare industry. With more than 30 years of innovation, Avel’s board-certified clinicians’ partner with hospitals, clinics, long-term care facilities, schools, EMS agencies, and correctional health systems nationwide to bring high-quality care to patients when and where it’s needed most. Learn more at: www.avelecare.com

Media Contact:
Jessica Gaikowski
Avel eCare
media@avelecare.com

SOURCE: Avel eCare

View the original press release on ACCESS Newswire

RALEIGH, NC / ACCESS Newswire / June 18, 2025 / iAccess Alpha’s Virtual Best Ideas Summer Investment Conference will take place on June 24-25, 2025, bringing together top micro-cap companies and investors for two days of high-quality insights and investing opportunities.

The event begins on Tuesday, June 24, 2025, with a series of live-streamed company presentations, beginning at 9:00 AM ET. The following day, Wednesday, June 25, will be dedicated to 1×1 meetings between presenting companies and investors, starting at 8:00 AM ET.

How to Attend:

Investors and industry professionals can register to watch the presentations and request 1×1 meetings by visiting the official event website: Register Here

Conference Schedule – June 24, 2025 (All Times ET):

Time	Company	Ticker	Webcast Link
9:00am	Inuvo Inc.	NYSE/AMEX:INUV	View Presentation
9:30am	Digi Power X Inc.	NASDAQ:DGXX /TSXV:DGX	View Presentation
10:00am	Surgepays Inc.	NASDAQ:SURG	View Presentation
10:30am	Coya Therapeutics Inc.	NASDAQ:COYA	View Presentation
11:00am	MIND Technoloy Inc.	NASDAQ:MIND	View Presentation
11:30am	Data IO Corp.	NASDAQ:DAIO	View Presentation
12:00pm	TBA	TBA	TBA
12:30pm	Upexi Inc.	NASDAQ:UPXI	View Presentation
1:00pm	DocGo Inc.	NASDAQ:DCGO	View Presentation
1:30pm	SKYX Platforms Corp.	NASDAQ:SKYX	View Presentation
2:00pm	HeartBeam Inc.	NASDAQ:BEAT	View Presentation
2:30pm	Heritage Global Inc.	NASDAQ:HGBL	View Presentation
3:00pm	Mobilicom Ltd.	NASDAQ:MOB	View Presentation
3:30pm	Envela Corp.	NYSE/AMEX:ELA	View Presentation

About iAccess Alpha’s Virtual Best Ideas Investment Conferences

iAccess Alpha hosts four virtual investment conferences annually (March, June, September, and December), showcasing high-potential small and micro-cap investment opportunities. The conferences feature live company presentations on Day 1, followed by exclusive 1×1 investor meetings on Day 2. Since 2019, iAccess Alpha has co-organized leading microcap-focused events, connecting top-tier investors with high-potential companies.

For more information, contact:
info@iaccessalpha.com
www.iaccessalpha.com

SOURCE: iAccess Alpha

View the original press release on ACCESS Newswire

NEW YORK CITY, NY / ACCESS Newswire / June 18, 2025 / Vero Technologies is pleased to announce its participation in the 2025 NIADA Convention & Expo, the premier annual gathering for the independent automobile dealer industry, taking place June 23-26 at the Fontainebleau Las Vegas.

CEO and Co-Founder John Mizzi and VP of Partnerships Jason Bartz will represent the company at the convention. Together, they’ll engage with specialty finance companies, auctions, and other lenders who provide critical financing solutions to independent dealers nationwide.

The NIADA Convention & Expo brings together thousands of independent automobile dealers and industry partners for four days of education, networking, and innovation. As the largest event in the independent auto industry, it provides an unparalleled platform for meaningful connections between dealers and the financial partners who support their businesses.

“Independent dealers are a critical part of the retail automotive ecosystem, and the lenders behind them often work with aging systems that create more friction than value,” said John Mizzi, CEO of Vero Technologies. “We’re looking forward to hearing firsthand how these providers are thinking about scale, compliance, and risk, and sharing how a modular approach like VeroOS can help streamline their day-to-day without disrupting what already works.”

Vero’s attendance at NIADA underscores the company’s focus on empowering lenders who serve the independent auto market. The convention will provide opportunities to explore how Vero’s technology platform can help these financial partners streamline their operations, reduce costs, and deliver superior service to their dealer customers.

About NIADA

The National Independent Automobile Dealers Association (NIADA) is among the nation’s largest trade associations, representing the used motor vehicle industry comprised of over 40,000 licensed dealers. Since 1946, NIADA has represented the voice and interests of used car dealers at the federal level in Washington D.C. Learn more at www.niada.com.

About Vero Technologies

Vero Technologies is a leading financial technology platform for asset finance, providing end-to-end solutions for wholesale finance, trade finance, equipment finance, and title management. Vero’s modular platform enables lenders to streamline loan servicing, risk monitoring, and operational workflows – enhancing efficiency while reducing costs.

To learn more, visit: www.vero-technologies.com.

Contact: Jason Bartz, info@vero-technologies.com, 404-383-7048

SOURCE: Vero Finance Technologies

View the original press release on ACCESS Newswire

NEWPORT BEACH, CALIFORNIA / ACCESS Newswire / June 18, 2025 / Amaze Holdings Inc. (NYSE American:AMZE) (“Amaze” or the “Company”), a global leader in creator-powered commerce, today announced, that new directors Pete Deutschman, Amrapali (Ami) Gan, and Sandie Hawkins were elected to its Board of Directors at the annual meeting of stockholders, effective June 12, 2025. The new appointees collectively will offer added corporate governance support and a diversified range of strategic insights to Amaze’s executive leadership team.

“With the expanded market opportunity and new strategic direction of our combined Company, we’ve accordingly bolstered our board of directors with an impressive group of industry veterans with deep ties to the creator economy,” Amaze Vice-Chairman Michael Pruitt said. “Our new board members offer a wide range of entrepreneurial experience and a deep knowledge across a variety of ecommerce, marketing, and creator-specific industries. On behalf of the rest of our board, I would like to welcome our newest members, and we look forward to benefiting from their contributions as we execute our mission to uplift and transform the creator economy.”

Pete Deutschman, Director

Pete Deutschman is Chief Buddy and Founder of The Buddy Group, an end-to-end creative marketing firm that helps brands engage with audiences and drive growth. At The Buddy Group, Deutschman has managed engagements with McDonald’s, American Express, Yamaha, and others. Deutschmanis also an advisor to a handful of technology start-ups, including Exfluential, Vessl, SailPlan, and DotLot, and is a board member for Project Hope Alliance.

Ami Gan, Director

Ami Gan is the Founder of HOXTON, a strategic advisory firm that blends strategy with creativity. Prior to founding HOXTON, Gan was the CEO of OnlyFans and led the company’s expansion into new creator segments globally. Gan also previously held various positions with global rapid-growth companies within disruptor industries including Cannabis Cafe, Red Bull Media House, and Quest Nutrition.

Sandie Hawkins, Director

Sandie Hawkins is the President at Teikametrics, an AI marketplace optimization platform, and has over 20 years of expertise in multi-channel marketing, business development, and digital innovation. Prior to this role, Hawkins served as General Manager of TikTok’s United States e-commerce business, where she launched TikTok shop and spearheaded the platform’s e-commerce strategy. She has also held various leadership roles at Adobe, Varick, and Rocket Fuel, where she developed high-performing teams, launched innovative digital solutions, and cultivated strategic partnerships.

Capitalization Update

The Company announced that the number of shares of common stock outstanding is 5,277,810 as of June 16, 2025, after taking into account the recent conversion of the Company’s Series D convertible preferred stock into common stock and the 1-for-23 reverse stock split effected on June 12, 2025.

For investor information, please contact IR@amaze.co

For press inquiries, please contact PR@amaze.co

About Amaze

Amaze Holdings, Inc. is an end-to-end, creator-powered commerce platform offering tools for seamless product creation, advanced e-commerce solutions, and scalable managed services. By empowering anyone to “sell anything, anywhere,” Amaze enables creators to tell their stories, cultivate deeper audience connections, and generate sustainable income through shoppable, authentic experiences. Discover more at www.amaze.co.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements relate to future events and developments or to our future operating or financial performance, are subject to risks and uncertainties and are based estimates and assumptions. Forward-looking statements may include, but are not limited to, statements about the reverse stock split, our market opportunity and potential growth of that market, strategies, initiatives, growth, revenues, expenditures, our plans and objectives for future operations, and future financial and business performance. These statements can be identified by words such as such as “may,” “might,” “should,” “would,” “could,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or “continue,” and are based our current expectations and views concerning future events and developments and their potential effects on us.

These statements are subject to known and unknown risks, uncertainties and assumptions that could cause actual results to differ materially from those projected or otherwise implied by the forward-looking statement. These risks include: our ability to execute our plans and strategies; our limited operating history and history of losses; our financial position and need for additional capital; our ability to attract and retain our creator base and expand the range of products available for sale; we may experience difficulties in managing our growth and expenses; we may not keep pace with technological advances; there may be undetected errors or defects in our software or issues related to data computing, processing or storage; our reliance on third parties to provide key services for our business, including cloud hosting, marketing platforms, payment providers and network providers; failure to maintain or enhance our brand; our ability to protect our intellectual property; significant interruptions, delays or outages in services from our platform; significant data breach or disruption of the information technology systems or networks and cyberattacks; risks associated with international operations; general economic and competitive factors affecting our business generally; changes in laws and regulations, including those related to privacy, online liability, consumer protection, and financial services; our dependence on senior management and other key personnel; and our ability to attract, retain and motivate qualified personnel and senior management.

Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other future filings and reports that we file with the Securities and Exchange Commission (SEC) from time to time. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the press release. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments.

SOURCE: Amaze Holdings, Inc.

View the original press release on ACCESS Newswire

ROSH HA‘AYIN, IL / ACCESS Newswire / June 18, 2025 / Brenmiller Energy Ltd. (“Brenmiller”, “Brenmiller Energy” or the “Company”) (NASDAQ:BNRG), a leading global provider of Thermal Energy Storage (“TES”) solutions for industrial and utility customers, today issued a letter from its Chief Executive Officer, Avi Brenmiller.

To Our Shareholders,

As previously announced, today at the close of trading on the Nasdaq Capital Market, Brenmiller Energy will implement a reverse share split-a strategic and proactive decision made to protect and preserve shareholder value as we approach a critical period of execution on our business objectives.

This decision followed extensive internal consideration about the timing and impact of a reverse share split. Ultimately, we determined that the best course of action was to be decisive today, which will allow us to remain focused on what matters most in the days ahead: delivering on our milestones.

The value that Brenmiller Energy has built is evident:

• More than a decade of TES innovation and $118 million in investments have led to deployments across Europe, the U.S., and the Middle East

• Commissioning and building over 100 MWh of projects

• A $500 million pipeline of commercial opportunities

• 4GWh of manufacturing capacity

Let us be clear: a reverse split changes the number of shares outstanding, but it does not impact your ownership.

All shareholders-including insiders-are impacted equally by this reverse split. That’s not incidental. It’s intentional. We are all in this together. Our Company’s founders and management, including myself, continue to have significant holdings in Brenmiller Energy. Investors can be assured that all of our interests are aligned.

As we are aiming to move towards key implementation milestones for commercial deployment in the near-term, with funding commitments for projects within our existing portfolio, and strategic collaborations-we believe that these future achievements will translate into tangible value for shareholders.

We’re not waiting for the market to understand what we’ve built. We are aiming to make it impossible to ignore.

As we’ve shared throughout 2025, we believe that Brenmiller Energy has entered a new phase-one defined by acceleration. Our recent progress with TES projects including Tempo Beverages in Israel and SolWinHy in Spain makes that clear: we believe we are on the verge of a breakout moment with a robust global commercial pipeline and technology that’s already proven in the field.

The result? Real operating momentum that we believe will spark interest in our technology-and a reappraisal of the value it truly deserves.

We thank you for standing with us, and we invite you to stay close. We believe that the weeks ahead won’t just validate our vision-they’ll define it.

Sincerely,

Avi Brenmiller
CEO, Brenmiller Energy Ltd.

About Brenmiller Energy Ltd.

Brenmiller Energy helps energy-intensive industries and power producers end their reliance on fossil fuel boilers. Brenmiller’s patented bGen™ ZERO thermal battery is a modular and scalable energy storage system that turns renewable electricity into zero-emission heat. It charges using low-cost renewable electricity and discharges a continuous supply of heat on demand and according to its customers’ needs. The most experienced thermal battery developer on the market, Brenmiller operates the world’s only gigafactory for thermal battery production and is trusted by leading multinational energy companies. For more information visit the Company’s website at https://bren-energy.com/ and follow the company on X and LinkedIn.

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements when it discusses: expected near-term milestones; the timing for implementing a reverse share split; its protecting and preserving shareholder value as the Company approaches a critical period of execution its business objectives;; the Company’s future commercial deployment milestones, funding commitments for projects within its existing portfolio, and strategic collaborations and that such future achievements will translate into tangible value for shareholders; future interest in the Company’s technology and a reappraisal of its value; and the Company’s $500 million pipeline of commercial opportunities. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. Factors that may affect the Company’s results include, but are not limited to: the Company’s planned level of revenues and capital expenditures; risks associated with the adequacy of existing cash resources; the demand for and market acceptance of our products; impact of competitive products and prices; product development, commercialization or technological difficulties; the success or failure of negotiations; trade, legal, social and economic risks; and political, economic and military instability in the Middle East, specifically in Israel. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (“SEC”) on March 4, 2025, which is available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact: investors@bren-energy.com

SOURCE: Brenmiller Energy

View the original press release on ACCESS Newswire

MIAMI, FL / ACCESS Newswire / June 18, 2025 / MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced that the first manuscript describing its lead drug candidate Ketamir-2, currently being evaluated in an ongoing Phase 1 clinical trial for neuropathic pain, has been accepted for publication in the peer-reviewed journal Frontiers in Pharmacology.

The article, titled “KETAMIR-2, A NEW MOLECULAR ENTITY AND NOVEL KETAMINE ANALOG,” authored by Itzchak Angel, Ph.D., MIRA’s Chief Scientific Advisor, highlights Ketamir-2’s pharmacological differentiation from ketamine and its potential as a next-generation CNS therapeutic.

Peer Review Validates Differentiated Pharmacology and Safety

Acceptance into Frontiers in Pharmacology provides external scientific validation by independent experts, underscoring the rigor and credibility of MIRA’s research. The publication confirms that Ketamir-2 was specifically engineered to overcome limitations associated with ketamine-such as poor oral bioavailability, dissociative side effects, and non-specific receptor binding.

Key Highlights from the Publication:

• Highly Selective, Cleaner Mechanism: Ketamir-2 is a low-affinity NMDA receptor antagonist that selectively targets the NMDA PCP site. Unlike ketamine, Ketamir-2 showed no significant interaction with over 40 other receptors, transporters, or ion channel targets-including dopamine, opioid, serotonin, and monoaminergic systems-highlighting its clean pharmacological profile and reduced off-target effects.

• No Hyperlocomotion, Even at High Doses: In contrast to ketamine, Ketamir-2 did not induce hyperlocomotion in preclinical models-a behavior associated with agitation and schizophrenia-like symptoms-suggesting a favorable neurobehavioral safety profile.

• Demonstrated Antidepressant and Anxiolytic Activity: In validated behavioral models (Open Field Test, Elevated Plus Maze, Forced Swim Test), Ketamir-2 demonstrated clear anxiolytic and antidepressant-like effects. Ketamine, used as a control, either showed no benefit or limited effect in most tests.

• Oral Delivery with Efficient Brain Penetration: All studies were conducted via the oral route. Ketamir-2 was shown to cross the blood-brain barrier and is not a substrate for P-glycoprotein, which often limits oral drug delivery to the brain. This may explain Ketamir-2’s ability to maintain CNS activity despite its lower NMDA receptor affinity.

“We are honored to see our foundational research on Ketamir-2 published in a high-impact scientific journal,” said Erez Aminov, CEO of MIRA. “This milestone adds meaningful scientific credibility and supports our confidence in Ketamir-2’s differentiated mechanism, favorable safety profile, and broad clinical potential.”

“This peer-reviewed publication provides clear validation of the differentiated pharmacological profile of Ketamir-2,” added Dr. Itzchak Angel, Chief Scientific Advisor. “Its clean pharmacological profile and safety make it a compelling next-generation alternative to ketamine.”

Clinical and Corporate Updates

MIRA also announced that its Phase 1 trial of Ketamir-2 is progressing as planned, with no safety concerns reported to date and dose escalation advancing. The Company expects to initiate a Phase 2a clinical trial in neuropathic pain by year-end 2025, pending regulatory clearance.

In addition, the Company is preparing new scientific data submissions and presentations to further support Ketamir-2’s clinical development and potential across CNS-related conditions.

MIRA also reaffirmed that the acquisition of SKNY Pharmaceuticals, which includes a first-in-class oral CB1/CB2 inverse agonist for obesity and smoking cessation (SKNY-1), is progressing on track. The Company has submitted the required regulatory filings for the merger to the U.S. Securities and Exchange Commission (SEC).

The publication will be available upon release at: www.frontiersin.org/journals/pharmacology

Cautionary Note Regarding Forward-Looking Statements

This press release and the statements of MIRA’s management related thereto contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA’s control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA’s potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA’s programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and other SEC filings, which are on file with the SEC at www.sec.gov and MIRA’s website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Helga Moya
info@mirapharma.com
(786) 432-9792

SOURCE: MIRA Pharmaceuticals

View the original press release on ACCESS Newswire

Regulatory Approval by the UK Financial Conduct Authority was Key Requirement for Transaction Timing

Minimal Conditions Remain for Deal Completion; Closing Expected in July, 2025

AUSTIN, TX AND NOTTINGHAM, UK / ACCESS Newswire / June 18, 2025 / Interactive Strength Inc. (NASDAQ:TRNR) (“TRNR” or the “Company”) today announced that it has received formal approval from the UK Financial Conduct Authority (“FCA”) for its previously-announced acquisition of Wattbike, the UK-based, omni-channel, connected, indoor-performance bike business, and that it expects to complete the acquisition in July, 2025.

The FCA’s approval satisfies a key condition for the closing of the acquisition, which is expected to significantly expand Interactive Strength Inc.’s presence in the global fitness market, particularly in the UK, and enhance its product offerings with a leading indoor-performance bike offering. This strategic acquisition is anticipated to be immediately accretive to TRNR’s results and accelerate growth, especially in key markets like the US and Germany, leveraging TRNR’s global distribution network.

Wattbike delivered over $15 million in 2024 revenue and has built on its prestigious elite-sport base – including Olympic teams, Premier League clubs, major US sports teams and elite fitness facilities – to debut a much broader product portfolio that will allow its footprint to scale internationally as well as in the UK, its home market.

“We have been waiting to secure FCA approval in order to finalize the Wattbike deal and now we will push to completion quickly,” said Trent Ward, Founder & CEO of Interactive Strength. “This regulatory hurdle was the main closing requirement the timing of which we did not control. The remaining steps are largely administrative. We’re already well underway integrating and collaborating with Wattbike, and we look forward to accelerating from here. Wattbike’s elite heritage, combined with TRNR’s Nasdaq listing, US distribution reach, and marketing muscle, positions us to drive meaningful growth across the UK, US, and Germany.”

“We remain thrilled to become part of the TRNR family,” added Stephen Loftus, CEO of Wattbike. “With FCA approval secured, we’re on the road to fully leverage TRNR’s global platform to accelerate our consumer and commercial expansion and bring premium, data-driven indoor cycling to new audiences.”

Wattbike is renowned for its high-performance connected indoor bikes, with deep penetration into leading UK gyms and an expanding direct-to-consumer customer base. The acquisition consideration is structured as an all-stock transaction for 100% of Wattbike, and there is an earn-out component to align the business’ financial performance with TRNR valuation. Further details regarding the financial impact of the acquisition will be provided in our upcoming filings with the U.S. Securities and Exchange Commission.

TRNR Media Contact

john@sintercompany.com

TRNR Investor Contact

ir@interactivestrength.com

About Interactive Strength Inc.:

Interactive Strength Inc. produces innovative specialty fitness equipment and digital fitness services under two main brands: 1) CLMBR and 2) FORME. Interactive Strength Inc. is listed on NASDAQ (symbol: TRNR).

CLMBR is a vertical climbing machine that offers an efficient and effective full-body strength and cardio workout. CLMBR’s design is compact and easy to move – making it perfect for commercial or in-home use. With its low impact and ergonomic movement, CLMBR is safe for most ages and levels of ability and can be found at gyms and fitness studios, hotels, and physical therapy facilities, as well as available for consumers at home. www.clmbr.com.

FORME is a digital fitness platform that combines premium smart gyms with live virtual personal training and coaching to deliver an immersive experience and better outcomes for both consumers and trainers. FORME delivers an immersive and dynamic fitness experience through two connected hardware products: 1) The FORME Studio Lift (fitness mirror and cable-based digital resistance) and 2) The FORME Studio (fitness mirror). In addition to the company’s connected fitness hardware products, FORME offers expert personal training and health coaching in different formats and price points through Video On-Demand, Custom Training, and Live 1:1 virtual personal training. www.formelife.com.

Forward Looking Statements:

This press release includes certain statements that are “forward-looking statements” for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements do not relate strictly to historical or current facts and reflect management’s assumptions, views, plans, objectives and projections about the future. Forward-looking statements generally are accompanied by words such as “believe”, “project”, “expect”, “anticipate”, “estimate”, “intend”, “strategy”, “future”, “opportunity”, “plan”, “may”, “should”, “will”, “would”, “will be”, “will continue”, “will likely result” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the possibility of completing this acquisition in July or at all, the business being accretive to earnings, accelerating growth in the UK, US or Germany. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company. Risks and uncertainties include but are not limited to: whether ATW Partners and / or DWF Labs will invest further amounts, other US publicly listed companies’ crypto strategies, and the price of $FET tokens. A further list and descriptions of these risks, uncertainties and other factors can be found in filings with the Securities and Exchange Commission. To the extent permitted under applicable law, the Company assumes no obligation to update any forward-looking statements.

# # #

SOURCE: Interactive Strength Inc.

View the original press release on ACCESS Newswire

Clear Start Tax Urges Families and Entrepreneurs to Act Before IRS Liens Create Long-Term Financial Consequences

IRVINE, CA / ACCESS Newswire / June 18, 2025 / Many Americans think of back taxes as a personal issue, but according to Clear Start Tax, the financial consequences can reach far beyond the individual. The national tax resolution firm is warning that unpaid tax debt can lead to aggressive IRS collection action, including federal tax liens, that may block property sales, impact business operations, and even interfere with a family’s ability to inherit property or assets.

As the IRS streamlines enforcement and invests in automation, liens are being filed faster – and impacting more people than ever.

“People assume tax debt is between them and the IRS,” said the Head of Client Solutions at Clear Start Tax. “But a lien follows you. It can block financing, derail business deals, and even affect your family’s ability to inherit what you leave behind.”

What Is a Federal Tax Lien – and Why It’s a Hidden Threat

Federal tax liens are one of the most powerful enforcement tools the IRS has. Once filed, a lien becomes public record and attaches to virtually everything the taxpayer owns, present and future. That includes homes, business assets, vehicles, and even financial accounts. Clear Start Tax says many people don’t fully understand the ripple effect a lien can have on both daily life and long-term goals.

Here are some of the key ways a federal tax lien can disrupt a taxpayer’s financial stability:

• Damaging credit scores, which limits access to mortgages, personal loans, or business funding

• Blocking property sales or refinancing, since the IRS has a legal claim over the asset

• Interfering with business operations, especially when assets are used as collateral

• Delaying or diminishing inheritance, because IRS liens must be satisfied before assets are transferred

By answering a few simple questions, taxpayers can find out if they’re eligible for the IRS Fresh Start Program and take the first step toward resolving their tax debt

Why Families and Business Owners Should Be Especially Cautious

While anyone can be affected by a tax lien, Clear Start Tax notes that families with estate plans and entrepreneurs with business holdings face the most serious consequences. These groups often have the most to lose if enforcement escalates.

Taxpayers in the following situations are particularly vulnerable:

• Business owners who rely on credit, property, or cash flow for daily operations

• Homeowners who need to refinance, sell, or use equity in their property

• Parents or grandparents looking to leave assets or property to their heirs

• Joint property owners who may be impacted, even if only one person has the tax debt

“Liens don’t just affect today’s finances,” said the Head of Client Solutions. “They can quietly erode tomorrow’s plans.”

How Clear Start Tax Helps Prevent or Resolve Federal Liens

The firm takes a proactive, client-centered approach to resolving tax debt before it leads to a lien – or to negotiate the removal of liens already filed. Clear Start Tax works directly with the IRS to protect clients’ assets and help them regain control of their financial future.

Their approach includes:

• Conducting thorough financial reviews to determine risk and eligibility for relief

• Creating personalized resolution strategies, such as Installment Agreements or Offer in Compromise

• Filing lien withdrawal or release requests, based on payment, hardship, or compliance

• Providing ongoing compliance support to prevent future liens or enforcement actions

Why Now Is the Time to Act

Clear Start Tax emphasizes that the best time to act is before a lien is filed. Once the IRS files a lien, the consequences grow quickly, and reversing the damage takes more time, paperwork, and cost. Whether you’re trying to protect a home, a business, or your family’s inheritance, waiting only increases the risk.

“Tax debt can create a domino effect that disrupts multiple generations if it’s not addressed early,” said the Head of Client Solutions. “We help people break that cycle before it gets written into the public record.”

About Clear Start Tax

Clear Start Tax is a full-service tax liability resolution firm that serves taxpayers throughout the United States. The company specializes in assisting individuals and businesses with a wide range of IRS and state tax issues, including back taxes, wage garnishment relief, IRS appeals, and offers in compromise. Clear Start Tax helps taxpayers apply for the IRS Fresh Start Program, providing expert guidance in tax resolution. Fully accredited and A+ rated by the Better Business Bureau, the firm’s unique approach and commitment to long-term client success distinguish it as a leader in the tax resolution industry.

Need Help With Back Taxes?

Click the link below:
https://clearstarttax.com/qualifytoday/
(888) 710-3533

Contact Information

Clear Start Tax
Corporate Communications Department
seo@clearstarttax.com
(949) 535-1627

SOURCE: Clear Start Tax

View the original press release on ACCESS Newswire